Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, State University of New York at Buffalo School of Medicine and Biomedical Sciences and School of Public Health and Health Professions, Buffalo, NY, USA.
Crit Care Med. 2011 Aug;39(8):1944-52. doi: 10.1097/CCM.0b013e31821bd79e.
Methicillin-resistant Staphylococcus aureus is an important cause of mortality among nosocomial infections. Recent investigations suggest that linezolid is superior to vancomycin in achieving clinical cure in patients with nosocomial pneumonia. We hypothesized that linezolid may exhibit anti-inflammatory properties in vivo model of pneumonia.
Prospective interventional study.
University affiliated laboratory.
BALB/c mice.
Three groups of BALB/c mice were inoculated with methicillin-resistant S. aureus American Type Culture Collection 33,591 to induce pneumonia. Each group (n = 6) underwent bronchoalveolar lavage at 24 hrs, 48 hrs, and 72 hrs after inoculation after treatment with vancomycin, linezolid, or no antibiotic. Bronchoalveolar lavage fluid levels of monocyte chemotactic protein-5 and interleukin-6 were quantified using cytometric bead array. Metalloproteinase-9 was detected by enzyme-linked immunosorbent assay and gelatin zymography. Neutrophil apoptosis in bronchoalveolar lavage was assessed by annexin V and 7-aminoactinomycin D staining. Neutrophil activity was determined by myeloperoxidase enzyme activity. Phagocytosis of apoptotic neutrophils by linezolid- vs. vancomycin treated-alveolar macrophages was examined in vitro.
Infected mice had a significant reduction in lung bacterial titers compared with controls (p < .05) after treatment with linezolid or vancomycin. There was no difference in bronchoalveolar lavage levels of monocyte chemotactic protein-5 or interleukin-6 between vancomycin- and linezolid-treated groups. Both antimicrobials were comparable in modulating the expression of matrix metalloproteinase-9 in bronchoalveolar lavage. Neutrophil apoptosis was comparable in both vancomycin- and linezolid-treated groups at all three time points. Vancomycin showed lower myeloperoxidase activity compared with linezolid in the first 24 hrs after inoculation (p = .03), but the difference was undetectable at 48 hrs and 72 hrs. Neither compound had an impact on the process of removal of apoptotic neutrophils by alveolar macrophages.
Linezolid did not display an advantage over vancomycin in modulating pulmonary innate immune response in a murine model of methicillin-resistant S. aureus pneumonia.
耐甲氧西林金黄色葡萄球菌是医院获得性感染导致死亡的一个重要原因。最近的研究表明,利奈唑胺在治疗医院获得性肺炎患者时比万古霉素更能达到临床治愈。我们假设利奈唑胺在肺炎的体内模型中可能具有抗炎特性。
前瞻性干预研究。
大学附属实验室。
BALB/c 小鼠。
三组 BALB/c 小鼠用耐甲氧西林金黄色葡萄球菌美国典型培养物集 33591 接种,以诱导肺炎。每组(n = 6)在接种后 24 小时、48 小时和 72 小时进行支气管肺泡灌洗,然后分别用万古霉素、利奈唑胺或无抗生素治疗。通过细胞因子微珠阵列定量检测支气管肺泡灌洗液中单核细胞趋化蛋白-5 和白细胞介素-6 的水平。通过酶联免疫吸附试验和明胶酶谱法检测基质金属蛋白酶-9。通过 Annexin V 和 7-氨基放线菌素 D 染色评估支气管肺泡灌洗液中中性粒细胞的凋亡。通过髓过氧化物酶酶活性测定中性粒细胞的活性。体外检查利奈唑胺与万古霉素处理的肺泡巨噬细胞对凋亡中性粒细胞的吞噬作用。
与对照组相比,感染小鼠的肺部细菌滴度在接受利奈唑胺或万古霉素治疗后显著降低(p <.05)。万古霉素和利奈唑胺治疗组之间的支气管肺泡灌洗液中单核细胞趋化蛋白-5 或白细胞介素-6 水平无差异。两种抗生素在调节支气管肺泡灌洗液中基质金属蛋白酶-9 的表达方面均相似。在所有三个时间点,万古霉素和利奈唑胺治疗组的中性粒细胞凋亡均相似。万古霉素在接种后 24 小时内的髓过氧化物酶活性低于利奈唑胺(p =.03),但在 48 小时和 72 小时时则无法检测到差异。两种化合物均未影响肺泡巨噬细胞对凋亡中性粒细胞的清除过程。
在耐甲氧西林金黄色葡萄球菌肺炎的小鼠模型中,利奈唑胺在调节肺部固有免疫反应方面没有优于万古霉素。